MRKR · Marker Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $500.0K | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $11.80M | $13.47M | $10.42M | $26.14M | $27.79M | $18.88M |
| SG&A | $4.18M | $4.24M | $7.48M | $12.82M | $12.92M | $10.47M |
| Total Operating Expenses | $16.44M | $17.71M | $17.89M | $38.96M | $40.72M | $29.35M |
| D&A | - | - | - | $2.79M | $2.15M | $485.6K |
| Operating Income | ($12.89M) | ($11.12M) | ($14.58M) | ($29.95M) | ($39.48M) | ($28.89M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | ($15.2K) | $50.0K | $3.7K | - | - | - |
| Net Income | ($12.16M) | ($10.73M) | ($8.24M) | ($29.93M) | ($41.88M) | ($28.71M) |
| EPS - Basic | ($0.79) | ($1.19) | ($0.94) | ($3.58) | ($6.10) | - |
| EPS - Diluted | ($0.79) | ($1.19) | ($0.94) | ($3.58) | ($6.10) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.07M | $19.19M | $15.11M | $11.78M | $42.35M | $21.35M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $793.7K | $1.07M | $961.0K | $1.61M | $5.14M | $2.94M |
| Current Assets | $19.07M | $22.02M | $17.13M | $16.62M | $45.98M | $24.41M |
| Total Assets | $19.07M | $22.02M | $17.13M | $34.42M | $68.14M | $45.61M |
| Current Liabilities | $2.27M | $3.46M | $3.07M | $7.78M | $12.90M | $6.40M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $2.27M | $3.46M | $3.07M | $14.82M | $24.15M | $18.27M |
| Stockholders' Equity | $16.80M | $18.56M | $14.05M | $19.60M | $43.99M | $27.34M |
| Retained Earnings | ($459.18M) | ($447.02M) | ($436.29M) | ($428.05M) | ($398.12M) | ($356.24M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($12.01M) | ($10.91M) | ($16.44M) | ($26.97M) | ($27.28M) | ($18.86M) |
| Investing Cash Flow | - | - | $18.66M | ($4.95M) | ($3.13M) | ($10.43M) |
| Financing Cash Flow | $9.86M | $14.99M | $1.11M | $202.1K | $52.56M | $6.74M |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | -7895.6% | - |
| EBITDA margin | - | - | - | - | -7465.8% | - |
| Net margin | - | - | - | - | -8375.8% | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | 5559.0% | - |
| SG&A / Revenue | - | - | - | - | 2585.0% | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -63.8% | -48.7% | -48.1% | -87.0% | -61.5% | -62.9% |
| Return on equity | -72.4% | -57.8% | -58.6% | -152.7% | -95.2% | -105.0% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 8.39 | 6.36 | 5.57 | 2.14 | 3.56 | 3.81 |
| Quick ratio | 8.39 | 6.36 | 5.57 | 2.14 | 3.56 | 3.81 |
| Cash ratio | 7.07 | 5.54 | 4.91 | 1.51 | 3.28 | 3.34 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.14 | 1.19 | 1.22 | 1.76 | 1.55 | 1.67 |
| Liabilities / Assets | 0.12 | 0.16 | 0.18 | 0.43 | 0.35 | 0.40 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | 0.01 | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 1.4x | 1.5x | 3.4x | 1.2x | 10.2x | - |
| P / S | - | - | - | - | 893.8x | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | 34.4% | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -15.9% | 23.7% | 51.3% | 24.1% | -36.7% | -28.2% |
| Net income growth (YoY) | -13.3% | -30.3% | 72.5% | 28.5% | -45.9% | -34.0% |
| EPS growth (YoY) | 33.6% | -26.6% | 73.7% | 41.3% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -9.5% | 32.1% | -28.3% | -55.4% | 60.9% | -38.0% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Marker Therapeutics against the 5 most active filers in the same SIC group.